Keywords: promising, ph, iib, data, transgene, nsclc, vacc

Promising Ph IIb data on Transgene NSCLC vacc

Article | 21 January 2008

Print This

France's Transgene has reported preliminary data from a Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in